Metropolis Healthcare has strengthened its presence in western Maharashtra with the acquisition of Kolhapur-based Ambika Pathology Laboratory for ₹17 crore through a slump sale agreement. The deal includes ₹1.7 crore as deferred consideration, with the remainder paid in cash.

Ambika operates a central laboratory with 12 patient touchpoints and generates nearly 75% of its revenue from B2C walk-ins. With this buyout, Metropolis aims to build a mini reference hub in Kolhapur that will serve surrounding districts, deepening its regional presence.

This marks Metropolis’ fourth acquisition in the past 10 months, aligning with its “String of Pearls” strategy to create strong diagnostic clusters. Maharashtra remains a crucial market, already contributing about 40% of the company’s overall revenues.

Financially, Ambika reported revenues of ₹6.69 crore in FY23, ₹7.09 crore in FY24, and ₹7.96 crore in FY25. The integration is expected to drive operational efficiencies, an expanded test menu, and stronger margins for the combined entity.

Also Read: Researchers at Stanford University design ‘Evo’- A fully functional AI viral genome

Industry observers note that the move reflects a wider consolidation trend in the diagnostics sector, where leading chains are acquiring regional players to expand reach and strengthen competitive positioning.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!